Clinical Portfolio and Pipeline

What's next

At Adaptive, we’re investing in the continued development of immune medicine products, which add new meaning to the stories every patient’s immune system has to tell.

Clinical Portfolio and Pipeline

MRD Business: clonoSEQ

Measure MRD

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

ALL

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

FDA cleared

Bone Marrow

CLIA Validated

Blood

CLL

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

FDA cleared

Bone Marrow

FDA cleared

Blood

MM

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

FDA cleared

Bone Marrow

CLIA Validated

Blood

NHL1

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

CLIA Validated

cfDNA (DLBCL)

CLIA Validated

Blood

Immune Medicine: T-Detect

Accurate Detection

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

SIGNAL
IDENTIFICATION

ALGORITHM
DEVELOPMENT

infectious-disease.png

INFECTIOUS
DISEASE

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

SIGNAL IDENTIFICATION

ALGORITHIM DEVELOPMENT

(FDA EUA)2

COVID-19

Lyme

autoimmune-icon.png

AUTOIMMUNE
DISEASES

EARLY
DEVELOPMENT

AV/CV

CLIA/FDA

COMMERCIALIZED

SIGNAL
IDENTIFICATION

ALGORITHIM
DEVELOPMENT

Crohn’s Disease

Multiple Sclerosis

Celiac Disease

Ulcerative Colitis

Rheumatoid Arthritis

Immune Medicine: Drug Discovery

CELL
THERAPY3

Exploratory

Discovery

IND-Ready

Clinical

1st Shared

2nd Shared
Personalized

Partner

v-1628590689440-header-logo.png

EXPLORATORY

DISCOVERY

IND-READY

CLINICAL

TCR-Treg

VACCINES

EXPLORATORY

DISCOVERY

IND-READY

CLINICAL

COVID-19

Partner

nykode-logo.png

ANTIBODIES4

EXPLORATORY

DISCOVERY

IND-READY

CLINICAL

COVID-19

Influenza A

Cancer (pMHCs)

Autoimmune (novel targets)

1 Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.
2 This product has received Emergency Use Authorization and is not FDA cleared or approved.
3 Product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The “1st Shared” and “2nd Shared” product candidates refer to the two lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to, the FDA.
4 Product candidates in development.